131 related articles for article (PubMed ID: 24760415)
1. ROS1 translocations and amplifications in lung cancer brain metastases.
Preusser M; Streubel B; Birner P
J Neurooncol; 2014 Jun; 118(2):425-426. PubMed ID: 24760415
[No Abstract] [Full Text] [Related]
2. ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy.
Lukas RV; Hasan Y; Nicholas MK; Salgia R
J Clin Neurosci; 2015 Dec; 22(12):1978-9. PubMed ID: 26159887
[TBL] [Abstract][Full Text] [Related]
3. Miliary brain metastases in a patient with ROS1-rearranged lung adenocarcinoma: a case report.
Dziadziuszko K; Szurowska E; Pienkowska J; Jassem J; Dziadziuszko R
J Thorac Oncol; 2014 May; 9(5):e34-6. PubMed ID: 24722162
[No Abstract] [Full Text] [Related]
4. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
[TBL] [Abstract][Full Text] [Related]
5. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.
Augustin J; Gabignon C; Scriva A; Menu L; Calmel C; Scatton O; Paye F; Fléjou JF; Praz F; Cervera P; Wendum D
Virchows Arch; 2020 Jul; 477(1):33-45. PubMed ID: 32447492
[TBL] [Abstract][Full Text] [Related]
6. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
Digumarthy SR; Mendoza DP; Lin JJ; Chen T; Rooney MM; Chin E; Sequist LV; Lennerz JK; Gainor JF; Shaw AT
Clin Lung Cancer; 2020 Mar; 21(2):153-159.e3. PubMed ID: 31708389
[TBL] [Abstract][Full Text] [Related]
7. ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases.
Warth A; Muley T; Dienemann H; Goeppert B; Stenzinger A; Schnabel PA; Schirmacher P; Penzel R; Weichert W
Histopathology; 2014 Aug; 65(2):187-94. PubMed ID: 24456475
[TBL] [Abstract][Full Text] [Related]
8. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
Lim SM; Kim HR; Lee JS; Lee KH; Lee YG; Min YJ; Cho EK; Lee SS; Kim BS; Choi MY; Shim HS; Chung JH; La Choi Y; Lee MJ; Kim M; Kim JH; Ali SM; Ahn MJ; Cho BC
J Clin Oncol; 2017 Aug; 35(23):2613-2618. PubMed ID: 28520527
[TBL] [Abstract][Full Text] [Related]
9. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer.
Preusser M; Berghoff AS; Ilhan-Mutlu A; Magerle M; Dinhof C; Widhalm G; Dieckmann K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; von Deimling A; Schoppmann SF; Zielinski CC; Streubel B; Birner P
Lung Cancer; 2013 Jun; 80(3):278-83. PubMed ID: 23453647
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
[TBL] [Abstract][Full Text] [Related]
11. Coexistence of three variants involving two different fusion partners of ROS1 including a novel variant of ROS1 fusions in lung adenocarcinoma: a case report.
Cai W; Li W; Ren S; Zheng L; Li X; Zhou C
J Thorac Oncol; 2014 Jun; 9(6):e43-6. PubMed ID: 24828671
[No Abstract] [Full Text] [Related]
12. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
13. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Gainor JF; Shaw AT
Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
[TBL] [Abstract][Full Text] [Related]
14. A genomic and clinicopathological study of non-small-cell lung cancers with discordant ROS1 gene status by fluorescence in-situ hybridisation and immunohistochemical analysis.
Zhao J; Chen X; Zheng J; Kong M; Wang B; Ding W
Histopathology; 2018 Jul; 73(1):19-28. PubMed ID: 29464758
[TBL] [Abstract][Full Text] [Related]
15. [Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib].
Svaton M; Pešek M
Klin Onkol; 2016; 29(1):63-5. PubMed ID: 26879065
[TBL] [Abstract][Full Text] [Related]
16. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization.
Luk PP; Selinger CI; Mahar A; Cooper WA
Arch Pathol Lab Med; 2018 Aug; 142(8):922-928. PubMed ID: 29902067
[TBL] [Abstract][Full Text] [Related]
18. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
19. Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer.
Sun TY; Niu X; Chakraborty A; Neal JW; Wakelee HA
J Thorac Oncol; 2019 Feb; 14(2):e21-e24. PubMed ID: 30217491
[No Abstract] [Full Text] [Related]
20. [Crizotinib Treatment Combined with Resection and Whole-brain Radiation Therapy
in A ROS1 Rearranged Lung Adenocarcinoma with Brain Metastasis:
Case Report and Literature Review].
Zhang M; Nie L; Zhang J
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):525-9. PubMed ID: 27561802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
